Table 1. Relation of hepatitis B genotype to disease states or drug effects.
| Positive association | Negative association |
| Precore G1896A mutation was e−ve and genotype D-specific, but G1862T mutation was e+ve and genotype A-specific63 | Disease states (acute hepatitis, chronic hepatitis, asymptomatic carriers, CLD or HCC), the hepatitis activity index and fibrosis stage and treatment response50 |
| 83% of G1862T mutations detected in genotype A cases vs, 17% in genotype D31 | Disease severity61 |
| Genotype D was associated with more severe liver disease in the incidentally-detected group, and was more prevalent in HCC patients of <40 years of age compared to the incidentally-detected group47 | Acute, fulminant and incidentally-detected disease59 |
| Genotype D:A = 2:1 in asymptomatic carriers, chronic hepatitis and CLD, but 1:1 in HCC. Precore G1896A in 46% of genotype D vs. 25% of genotype A51 | CLD, chronic hepatitis or HCC cases49 |
| Genotype D achieved higher SVR on LAM therapy than did genotype A48 | Responders and non-responders to LAM therapy48 |
| In the >25 year-old age subgroup, genotype A is more often associated with CLD than is genotype D58 | Long-term response to TDF therapy62 |
| More genotype A patients had Child class C disease57 | LAM response and YMDD mutation86 |
| Genotype C is associated with higher viral load, e+ve disease and increased risk of CLD54 | ETV response101 |
| bcp and pc mutations were more frequent in genotype D cases compared with genotype A cases61 | |
| Genotype D cases showed significantly high acute hepatitis, whereas genotype C cases showed higher chronic hepatitis60 | |
| All non-responders to ETV/TDF had genotype D103 | |
| Genotype A or mixed genotype cases are more likely to undergo inter-genotype switch on long-term TDF therapy compared to genotype D cases62 | |
| HCC patients infected with genotype A were significantly younger than those infected with genotype D. pc mutation G1862T and bcp mutation C1766T/T1768A were more frequent in genotype A cases and significantly associated with HCC44 |
Abbreviations: LAM, lamivudine; ETV, entecavir; TDF, tenofovir; e+ve, HBeAg-positive; CLD, chronic liver disease; HCC, hepatocellular carcinoma; pc, precore; bcp, basal core promoter.